Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Office Chief Counsel maintains continuity of temporariness

Executive Summary

David Dorsey, a long-time staffer for Sen. Ted Kennedy, D-Mass., is expected to be the Obama Administration's pick for FDA chief counsel (1"The Pink Sheet," Jan. 19, 2009, p. 3). The choice would be one with a bit of continuity; Dorsey worked in the office of FDA's chief counsel before moving to the Hill. In the meantime, though, FDA is opting for continuity of its own during the transition: Deputy Chief Counsel Jeffrey Senger will be reprising his brief 2007 role by serving as acting chief counsel (2"The Pink Sheet," Sept. 10, 2007, p. 12)

Related Content

Opioid Approval Delay? Class REMS Poses Legal Questions For Pending Drugs
Race For White Oak Almost Over: Will It End With Sharfstein Or Califf At FDA?
FDARA Citizen Petition Provisions No “Silver Bullet,” Bradshaw Tells GPhA





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts